Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Stock Has Average Price Target of $15.86 According to Analysts

Shares of Inventiva S.A. Sponsored ADR (NASDAQ:IVA) have been assigned a consensus rating of “Buy” from the ten brokerages that are currently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating, seven have issued a buy rating and two have given a strong buy rating to the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $15.86.

Several equities analysts have commented on IVA shares. Guggenheim raised their target price on shares of Inventiva from $11.00 to $14.00 and gave the company a “buy” rating in a report on Tuesday, September 15th. Piper Sandler reaffirmed an “overweight” rating on shares of Inventiva in a report on Wednesday, September 16th. Cantor Fitzgerald initiated coverage on shares of Inventiva in a research report on Friday, July 17th. They set an “overweight” rating on the stock. Wall Street Zen raised shares of Inventiva from a “sell” rating to a “hold” rating in a research note on Saturday, October 3rd. Finally, Truist Financial boosted their price objective on shares of Inventiva from $13.00 to $18.00 and gave the company a “buy” rating in a research report on Friday, October 2nd.

Inventiva Price Performance

IVA opened at $3.65 on Monday. Inventiva has a 52-week low of $2.82 and a 52-week high of $7.29. The business’s fifty day moving average is $3.82 and its 200-day moving average is $4.89.

Inventiva (NASDAQ:IVA) last issued its quarterly earnings results on Friday, August 14th. The company reported ($0.14) EPS for the quarter. The company had revenue of $0.75 million during the quarter. On average, research analysts expect that Inventiva will post -0.79 earnings per share for the current year.

Hedge Funds Weigh In On Inventiva

Several hedge funds and other institutional investors have recently modified their holdings of the business. Seven Fleet Capital Management LP bought a new stake in shares of Inventiva during the 1st quarter worth $1,111,000. Engineers Gate Manager LP grew its position in Inventiva by 155.5% in the second quarter. Engineers Gate Manager LP now owns 71,116 shares of the company’s stock valued at $269,000 after acquiring an additional 43,280 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its position in Inventiva by 78.7% in the third quarter. China Universal Asset Management Co. Ltd. now owns 38,600 shares of the company’s stock valued at $142,000 after acquiring an additional 17,000 shares during the last quarter. Finally, Platt Investment Counsel LLC bought a new position in Inventiva in the third quarter valued at about $45,000. Institutional investors own 19.06% of the company’s stock.

Inventiva Company Profile

Inventiva SA is a clinical-stage biopharmaceutical company headquartered in Daix, France. Founded in 2011, the company focuses on developing oral treatments for metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease associated with metabolic disorders.

Inventiva’s lead drug candidate is lanifibranor, an investigational pan-peroxisome proliferator-activated receptor (pan-PPAR) agonist being evaluated in the Phase 3 NATiV3 clinical trial.